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drugs; neither patient had used any new
drug other than the chemotherapy
agents. It has been reported that plati-
num rarely causes acute lung injury4; so
we, therefore, concluded that pem-
etrexed was the offender in both cases.
Several risk factors have been iden-
tified regarding gefitinib; smoking habit,
male sex, coexistence of interstitial pneu-
monia, early onset of disease, and poor
performance status.5 In both our cases,
many of these risk factors were found.
Because the role of pemetrexed in
the treatment of solid tumors continues to
expand, clinicians must be aware of this
possible severe pulmonary complication
during the management of patients with
treatment regimens that include pemetrexed.
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Evaluation of Kras Gene
Mutation and Copy
Number in Thymic
Carcinomas and
Thymomas
To the Editor:
Compared with the more common
epithelial cancers, current knowledge
about the biology of thymic epithelial
tumors is limited. Research has been
hampered by the rarity of the tumor and
the lack of established cell lines and
animal models. Ras family plays impor-
tant roles in the regulatory processes of
proliferation, differentiation, and apo-
ptosis. A recent Caucasian report dem-
onstrated that 1 of 38 thymoma and 1 of
7 thymic carcinoma had Kras muta-
tions.1 Because we previously reported
the EGFR copy number2 and Kras muta-
tion3 status using quantitative polymerase
chain reaction (PCR) assay in non-small
cell lung cancer, we evaluated the Kras
gene mutation status and Kras gene am-
plification, which may bring important in-
formation for the surgically treated Japa-
nese thymic epithelial tumor patients.
Thymic epithelial tumor tissues
were obtained by surgical excision from
125 patients (107 thymomas and 18 thy-
mic cancers). Kras mutation status at
codon 12,13 mutation was analyzed by
quantitative real-time PCR performed us-
ing LightCycler.3 Positive sample and
some of the negative samples from melt-
ing analysis were directly sequenced. Us-
ing the LightCycler genotyping PCR as-
say, only one thymic carcinoma case was
detected to have a Kras mutation. A het-
erozygous G to T substitution at nucleo-
tide position 35 in exon 1 of Kras, result-
ing in a valine for glycine amino acid
substitution at position 12 (G12V) (Fig-
ure 1). This patient was a 38-year-old
woman with adenocarcinoma. She is a
never smoker and had stage IVb cancer
with lung metastasis. EGFR mutations
were evaluated for 105 thymomas and 11
thymic carcinomas using LightCycler
genotyping assay.4 However, no muta-
tion was found within the cohort. In lung
cancers, Krasmutation rate was lower in
Japanese when compared with Cauca-
sian.3 The difference between the previ-
ously published study1 and ours might
be caused by the difference in ethnicity:
Caucasian or Oriental. Characteristi-
cally, 70% of Kras mutations are G to T
transversions,5 molecular events that are
linked to exposure to tobacco smoke
carcinogenesis. A previous report also
showed that the mutation case from thy-
mic carcinoma was a heterozygous G to
T transversion at nucleotide position 35
in exon 1 of Kras.1 Although, in our
case, the patient was a nonsmoker, other
mechanisms such as passive tobacco
smoking might be involved.
Kras copy number was analyzed
for 13 thymic cancer and 19 advanced
thymoma patients by quantitative real-
time PCR performed on 7500 Real Time
PCR System (Applied Biosystems) by
using a QuantiTect SYBR Green Kit
(Qiagen, Inc., Valencia, CA).2 Only one
of the 13 thymic cancer case was found
to have increased Kras copy number
(3.0). This patient was a 76-year-old
man with squamous cell carcinoma. He
had stage IVb cancer with lymph node
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FIGURE 1. The data for Kras gene using direct sequencing. Left, A heterozygous G to
T substitution at nucleotide position 35 in exon 1 of Kras, resulting in a valine for gly-
cine amino acid substitution at position 12 (G12V). Right, Reverse sequencing.
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and lung metastasis. He died 2 months
after surgery. He had wild-type Kras
and EGFR gene. Of 19 thymomas, we
detected only one case with increased
Kras copy number.
Advanced thymic carcinoma is a
very aggressive disease. To date, there
are no established treatment options for
the refractory and recurrent disease, and
few prospective trials were conducted in
patients with thymic carcinoma. Re-
sponses to EGFR tyrosine kinase inhib-
itors have been rare in unselected thy-
mic tumors. Coupled with the data on
Kras and EGFR mutations could explain
the findings. Kras mutations predict for
primary resistance to anti-EGFR thera-
pies, gefitinib/erlotinib in lung cancer,
and cetuximab in colon cancer. These
findings could have therapeutic implica-
tions for the treatment of thymic tumors.
Although Kras mutations or increased
copy number are rare in thymic tumors,
further assessment of Kras is needed
and should be included in any therapeu-
tic trial considering anti-EGFR therapy
for thymic malignancies.
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Leptomeningeal
Metastases from Small
Cell Lung Cancer
Responsive to
Temozolomide
Therapy
To the Editor:
Leptomeningeal spread of small
cell lung cancer (SCLC) is extremely
difficult to treat. Symptoms typically
progress rapidly, and the prognosis is
poor with a median survival of 1.3
months.1 Temozolomide, a nonclassic
oral alkylating agent with penetra-
tion into the central nervous system, is
a standard therapy for glioblastoma
multiforme and refractory astrocy-
toma. Herein, we report two patients
with leptomeningeal metastases from
SCLC who received temozolomide
and had dramatic improvement of their
disease.
PATIENT 1
A 53-year-old man, former 37
pack-year smoker, was diagnosed with
SCLC after presenting with limbic en-
cephalitis. He received six cycles of
etoposide and cisplatin with concur-
rent radiation therapy to the thorax. A
brain metastasis was irradiated and
then resected because of increased
symptoms. Subsequent imaging re-
vealed new brain lesions and plaque-
like leptomeningeal spread. Temozo-
lomide was started at 75 mg/m2 for 21
days of a 28-day cycle and modified to
125 mg/m2 for 5 days because of grade
4 thrombocytopenia. Imaging 10
weeks after starting temozolomide
showed significant interval improve-
ment. Unfortunately, an magnetic res-
onance imaging of the spine 6 weeks
later showed progression.
PATIENT 2
A 61-year-old woman, former 44
pack-year smoker, was diagnosed with
SCLC after presenting with postob-
structive pneumonia. She received five
cycles of carboplatin and etoposide
and radiation to alleviate left main
stem bronchus obstruction. She also
received whole brain radiation for a
lesion on the third ventricle. Imaging 4
months later revealed extensive lepto-
meningeal disease (Figure 1A). She
started temozolomide 150 mg/m2 for 5
days every 21 days. Repeat imaging
after 7.5 weeks showed significant im-
provement (Figure 1B). Follow-up
magnetic resonance imagings showed
maintained response at 6 weeks but
progression at 18 weeks.
For over 40 years, alkylating agents
have demonstrated efficacy in SCLC. Al-
kylators produce specific DNA lesions
that, when left unrepaired, lead to cytotox-
icity and apoptosis. The MGMT (O6-
methyl-guanine-DNA methyltransferase)
gene encodes a DNA-repair protein that
is irreversibly inactivated with each re-
pair of alkylator-induced damage.
Availability of MGMT may therefore be
an important determinant of treatment
failure with alkylators.2 In addition,
methylation of the MGMT promoter
may affect sensitivity to alkylating
agents,2 and aberrant methylation of
MGMT is found in SCLC.
To better characterize temozolo-
mide activity in SCLC, we are conduct-
ing a phase II trial of temozolomide as
second- or third-line therapy for SCLC.
Patients with brain metastases are eligi-
ble but leptomeningeal disease is ex-
cluded because of the poor prognosis.
Preliminary data were presented at the
International Association for the Study
of Lung Cancer meeting in 2009. Of
note, regression of brain metastases in
three patients previously treated with
cranial radiation was observed.3
Herein, we reported the dramatic
responses of SCLC leptomeningeal dis-
ease to temozolomide in two patients.
The responses may not be durable, but
this treatment clearly improved survival
for these patients. Based on these robust
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